The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma
Abstract
Background and aims: Golgi protein 73 (GP73) as a potential serum marker for hepatocellular carcinoma (HCC) has not been validated in large cohort studies. Furthermore, its significance in the assessment of tumour recurrence after HCC resection remains unknown. The aim of this study was to determine the value of serum GP73 in the diagnosis of HCC. Methods: Serum GP73 and alpha-fetoprotein (AFP) were compared in a total of 4217 human subjects in this multicentre study, including 1690 healthy adults, 337 hepatitis B virus (HBV) carriers, 512 patients with cirrhosis, 789 patients with HCC, 61 patients with other malignant liver lesions, 206 patients with benign liver lesions and 622 patients with 14 different kinds of non-liver cancers. The main outcome measures were the specificity and sensitivity of GP73 in patients at risk for the development of HCC. Results: Using 8.5 relative units as a cut-off value, the sensitivity and specificity of serum GP73 for HCC were 74.6% (95% CI 71.5% to 77.6%) and 97.4% (95% CI 96.8 to 98.3%), compared with 58.2% (95% CI 55.2% to 62.1%) and 85.3% (95% CI 83.4% to 88.1%) for AFP (p<0.001) using 35 ng/ml as a cut-off value. The GP73 level was significantly increased in patients with HCC compared with healthy controls (14.7 vs 1.2, p<0.001). Although GP73 levels in HBV carriers (2.9) and patients with cirrhosis (4.7) were somewhat elevated, they were much lower than that in patients with HCC (p<0.001). GP73 decreased following surgical resection of HCC lesions and increased with tumour recurrence. Fourteen types of non-liver cancers were analysed; all the benign and other malignant liver lesions had moderate elevations of GP73, albeit at a much lower level than in HCC. Conclusions: GP73 is an accurate serum marker for the detection of HCC and its recurrence after surgery, with higher sensitivity and specificity than AFP. Clinical implementation of serum GP73 measurement as a standard test for HCC is recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Prognostic prediction and treatment strategy in hepatocellular carcinoma
Bruix, J., & Llovet, J. M. (2002) · Hepatology · doi:10.1053/jhep.2002.32089 · Cited by 1,099
Hepatocellular Carcinoma – Epidemiological Trends and Risk Factors
Schütte, K., Bornschein, J., & Malfertheiner, P. (2009) · Digestive Diseases · doi:10.1159/000218339 · Cited by 441
Block, T. M., Comunale, M. A., Lowman, M., Steel, L. F., Romano, P. R., Fimmel, C., Tennant, B. C., London, W. T., Evans, A. A., Blumberg, B. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408928102 · Cited by 372
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma
Marrero, J. A., Romano, P. R., Nikolaeva, O., Steel, L., Mehta, A., Fimmel, C. J., Comunale, M. A., D'Amelio, A., Lok, A. S., & Block, T. M. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.05.028 · Cited by 364
Shariff, M. I., Cox, I. J., Gomaa, A. I., Khan, S. A., Gedroyc, W., & Taylor-Robinson, S. D. (2009) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.35 · Cited by 333
Hepatitis B‐related hepatocellular carcinoma: epidemiological characteristics and disease burden
Nguyen, V. T. T., Law, M. G., & Dore, G. J. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2009.01117.x · Cited by 302
GP73, a novel Golgi-localized protein upregulated by viral infection
Kladney, R. D., Bulla, G. A., Guo, L., Mason, A. L., Tollefson, A. E., Simon, D. J., Koutoubi, Z., & Fimmel, C. J. (2000) · Gene · doi:10.1016/s0378-1119(00)00136-0 · Cited by 276
Schwegler, E. E., Cazares, L. H., Steel, L. F., Adam, B.-L., Johnson, D. A., Semmes, O. J., Block, T. M., Marrero, J. A., & Drake, R. R. (2005) · Hepatology · doi:10.1002/hep.20577 · Cited by 132
Fimmel, C. J., & Wright, L. M. (2009) · Hepatology · doi:10.1002/hep.22994 · Cited by 41
Cited by
GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis
Ye, Q.-H., Zhu, W.-W., Zhang, J.-B., Qin, Y., Lu, M., Lin, G.-L., Guo, L., Zhang, B., Lin, Z.-H., Roessler, S., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.07.017 · Cited by 228
Metadata
- Authors
- Mao, Y., Yang, H., Xu, H., Lu, X., Sang, X., Du, S., Zhao, H., Chen, W., Xu, Y., Chi, T., Yang, Z., Cai, J., Li, H., Chen, J., Zhong, S., Mohanti, S. R., Lopez-Soler, R., Millis, J. M., Huang, J., & Zhang, H.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2010-09-28
- Volume
- 59
- Issue
- 12
- Pages
- 1687-1693
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2162519578
- Cited by
- 266
- References
- 13
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. https://app.cochat.ai/papers/10.1136/gut.2010.214916
- The paper
- Mao, Y., Yang, H., Xu, H., Lu, X., Sang, X., Du, S., Zhao, H., Chen, W., Xu, Y., Chi, T., Yang, Z., Cai, J., Li, H., Chen, J., Zhong, S., Mohanti, S. R., Lopez-Soler, R., Millis, J. M., Huang, J., & Zhang, H. (2010). Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. https://doi.org/10.1136/gut.2010.214916
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
